News Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
42.05 ^USD	-0.12%		-0.02%	-0.83%

May. 14	Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	MT
May. 08	Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NOTICE OF INVESTIGATION: Kaskela Law LLC Announces Shareholder Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the Firm	May. 20	PR
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	May. 14	MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	Apr. 19	AQ
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Apr. 18	MT
Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study	Apr. 18	MT
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study	Apr. 18	RE
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	Apr. 18	AQ
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson?s Disease	Apr. 18	CI
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	Mar. 04	MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 22	MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions	Feb. 22	MT
Phew! The party continues!	Feb. 22
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports	Feb. 21	RE
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20	MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Summary

Filters